SCHEMBL20415165

SCHEMBL20415165

CN1CCN(CCC(=O)/C(=C\c2ccc(Cl)cc2)c2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.53
MAPT P10636 2/20 0.53
CHRM1 P11229 1/20 0.53
TP53 P04637 1/20 0.52
HTR1A P08908 3/20 0.50
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
CNR1 P21554 1/20 0.44
HTR7 P34969 1/20 0.44
AKR1C3 P42330 3/20 0.43
AKR1C2 P52895 2/20 0.43
AKR1C1 Q04828 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.42
KCNA5 P22460 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24495791 0.90 KMT2A (0.51) HPGDMAPTCHRM1HTR1ALMNA
SCHEMBL20415341 0.77 OPRK1 (0.48) HPGDMAPTCHRM1TP53HTR1A
SCHEMBL24495795 0.76 AKR1C1 (0.48) MAPTLMNAAKR1C3AKR1C2AKR1C1
SCHEMBL20415160 0.74 TMEM97 (0.55) TP53AKR1C3AKR1C2AKR1C1SMN1; SMN2
SCHEMBL20415228 0.74 TMEM97 (0.55) TP53AKR1C3AKR1C2AKR1C1SMN1; SMN2
SCHEMBL29293636 0.74 HSP90AA1 (0.39) HPGDHTR1ALMNAAKR1C3AKR1C2
SCHEMBL29293741 0.73 HTT (0.46) MAPTLMNAL3MBTL1AKR1C3AKR1C2
Hydrochloric Acid SCHEMBL29073235 0.73 TMEM97 (0.54) AKR1C3AKR1C2AKR1C1SMN1; SMN2
SCHEMBL29293643 0.73 HTR1A (0.44) HPGDMAPTCHRM1HTR1ALMNA
SCHEMBL5954175 0.72 KMT2A (0.70) HPGDMAPTTP53HTR1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4397652-A2 3-(PHENYL)-2-(AMINOMETHYL)-1-PHENYL-2-PROPEN-1-ONE DERIVATIVES AS INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR FOR TREATING PROSTATE CANCER The Regents of the University of California (US) 2024-07-10 EP disclosed
US-20220177418-A1 INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-09 US disclosed
WO-2018136792-A1 INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177418-A1 INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR AR, BRDT, NR5A1 HPGD 2809/4885MAPT 3693/4885CHRM1 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.